R. Bryan Barriger, MD

Articles by R. Bryan Barriger, MD

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

ByJoe Yujiao Chang, MD, PhD,Larry L. Kestin, MD,R. Bryan Barriger, MD,Indrin J. Chetty, PhD,Mark E. Ginsburg, MD,Sanath Kumar, MD,Billy W. Loo, Jr, MD, PhD,Benjamin Movsas, MD,Andreas Rimner, MD,Kenneth E. Rosenzweig, MD,Thomas E. Stinchcombe, MD,Gregory M. M. Videtic, MD, CM,Henning Willers, MD

August 15th 2014

The treatment of inoperable stage III non–small-cell lung cancer (NSCLC) remains a challenge due to high rates of distant metastasis, local recurrence, and toxicity associated with definitive therapy.

Latest Updated Articles

Uptake of Nononcology Gene Therapy Remains Slow in Hematology
Published: August 16th 2024 | Updated: August 19th 2024
Phase 3 Trial Seeks to Continue Supporting Arsa-Cel Gene Therapy for MLD
Published: March 18th 2024 | Updated: June 3rd 2024
Rapcabtagene Autoleucel Shows Promise for DLBCL in Updated Phase 2 Data
Published: December 7th 2024 | Updated:
Aimee C. Talleur, MD, on Predicting Response and Toxicity to Cell Therapy
Published: December 12th 2022 | Updated:
RPE Cell Therapy Shows Improvements in Early GA With AMD
Published: July 14th 2024 | Updated:
Multi-Characteristic Opsin Gene Therapy for Retinitis Pigmentosa Improves Multiple Measures of Vision
Published: May 18th 2023 | Updated:

R. Bryan Barriger, MD

Articles by R. Bryan Barriger, MD

ACR Appropriateness Criteria® Nonsurgical Treatment for Locally Advanced Non–Small-Cell Lung Cancer: Good Performance Status/Definitive Intent

Latest Updated Articles

Trending on CGTlive®

Sanofi’s Neovascular Age-Related Macular Degeneration Gene Therapy SAR402663 Garners FDA Fast Track Designation

Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025

Daniel Galbraith, PhD, on Using Targeted Locus Amplification to Analyze Genetically Modified Cells